文献速递浆细胞疾病

具有浆细胞白血病样转录组特征的高危多发性骨髓瘤的识别

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.
PubMed 文献 · J Clin Oncol · 2022-03-31

研究基于循环肿瘤细胞水平与肿瘤转录组构建了浆细胞白血病样疾病的转录组分类器,在154例新诊断多发性骨髓瘤和29例原发性浆细胞白血病患者中构建与验证,并在2139例新诊断多发性骨髓瘤独立队列中评估预后价值。分类器识别原发性浆细胞白血病的敏感性为93%,将10%的新诊断多发性骨髓瘤归类为浆细胞白血病样,该状态在多因素分析中与更差的无进展生存和总生存独立相关。

要点

  • 高循环肿瘤细胞水平与1700个基因表达相关,独立于肿瘤负荷(错误发现率<0.05)。
  • 基于54个基因的转录组分类器识别原发性浆细胞白血病的敏感性为93%。
  • 10%的新诊断多发性骨髓瘤被分类为浆细胞白血病样,其无进展生存HR 1.64、总生存HR 1.89。

核心结论

  • 原发性浆细胞白血病基于特定肿瘤转录组被识别,该转录组也存在于临床未表现为白血病的高危新诊断多发性骨髓瘤患者中。
  • 将浆细胞白血病样状态纳入现行新诊断多发性骨髓瘤风险模型可能提高预后准确性。

研究设计与样本

  • 利用Cassiopeia或HO143试验中154例新诊断多发性骨髓瘤患者及EMN12/HO129试验中29例原发性浆细胞白血病患者的基线循环肿瘤细胞水平、肿瘤负荷和肿瘤转录组信息,生物信息学构建并验证浆细胞白血病样疾病的转录组分类器。
  • 在来自HOVON-65/GMMG-HD4、HOVON-87/NMSG-18、EMN02/HO95、MRC-IX、Total Therapy 2、Total Therapy 3和MMRF CoMMpass研究的2139例新诊断多发性骨髓瘤独立队列中评估其预后价值。

主要发现

  • 高循环肿瘤细胞水平与1700个基因的表达相关,独立于肿瘤负荷(错误发现率<0.05)。
  • 通过留一交叉验证选择54个基因构建代表浆细胞白血病样疾病的转录组分类器,在验证队列中识别原发性浆细胞白血病的敏感性为93%,并将10%的新诊断多发性骨髓瘤肿瘤分类为浆细胞白血病样。
  • 浆细胞白血病样多发性骨髓瘤在转录组和细胞遗传学上类似于原发性浆细胞白血病,但循环肿瘤细胞水平和肿瘤负荷显著更低。
  • 在新诊断多发性骨髓瘤的多因素分析中,校正修订版国际分期系统分期、年龄和治疗后,浆细胞白血病样状态对无进展生存(风险比1.64;95%CI 1.30至2.07)和总生存(风险比1.89;95%CI 1.42至2.50)均具有显著预后价值。

关键数值与推荐

  • 原发性浆细胞白血病与初诊多发性骨髓瘤的区分基于循环肿瘤细胞≥20%。
  • 转录组分类器识别原发性浆细胞白血病的敏感性为93%。
  • 10%的新诊断多发性骨髓瘤被分类为浆细胞白血病样。
  • 浆细胞白血病样状态的无进展生存风险比1.64(95%CI 1.30至2.07),总生存风险比1.89(95%CI 1.42至2.50)。

临床怎么用

  • 作者认为将浆细胞白血病样状态纳入现行新诊断多发性骨髓瘤风险模型可能提高预后准确性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Primary plasma cell leukemia (pPCL) is an aggressive subtype of multiple myeloma, which is distinguished from newly diagnosed multiple myeloma (NDMM) on the basis of the presence of ≥ 20% circulating tumor cells (CTCs). A molecular marker for pPCL is currently lacking, which could help identify NDMM patients with high-risk PCL-like disease, despite not having been recognized as such clinically. METHODS: A transcriptomic classifier for PCL-like disease was bioinformatically constructed and validated by leveraging information on baseline CTC levels, tumor burden, and tumor transcriptomics from 154 patients with NDMM included in the Cassiopeia or HO143 trials and 29 patients with pPCL from the EMN12/HO129 trial. Its prognostic value was assessed in an independent cohort of 2,139 patients with NDMM from the HOVON-65/GMMG-HD4, HOVON-87/NMSG-18, EMN02/HO95, MRC-IX, Total Therapy 2, Total Therapy 3, and MMRF CoMMpass studies. RESULTS: High CTC levels were associated with the expression of 1,700 genes, independent of tumor burden (false discovery rate < 0.05). Of these, 54 genes were selected by leave-one-out cross-validation to construct a transcriptomic classifier representing PCL-like disease. This not only demonstrated a sensitivity of 93% to identify pPCL in the validation cohort but also classified 10% of NDMM tumors as PCL-like. PCL-like MM transcriptionally and cytogenetically resembled pPCL, but presented with significantly lower CTC levels and tumor burden. Multivariate analyses in NDMM confirmed the significant prognostic value of PCL-like status in the context of Revised International Staging System stage, age, and treatment, regarding both progression-free (hazard ratio, 1.64; 95% CI, 1.30 to 2.07) and overall survival (hazard ratio, 1.89; 95% CI, 1.42 to 2.50). CONCLUSION: pPCL was identified on the basis of a specific tumor transcriptome, which was also present in patients with high-risk NDMM, despite not being clinically leukemic. Incorporating PCL-like status into current risk models in NDMM may improve prognostic accuracy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hofste Op Bruinink D, Kuiper R, van Duin M, et al. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. J Clin Oncol. 2022. PMID: 35357885. doi:10.1200/JCO.21.01217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。